Business Context and Reporting Period
Company: Launch One Acquisition Corp. (SPAC), a Cayman Islands exempted company.
Reporting Date: June 25, 2025.
Event: Execution of a Business Combination Agreement with Minovia Therapeutics Ltd., an Israeli biotechnology company. The transaction involves a merger structure where Minovia and Launch One will become wholly-owned subsidiaries of a new public entity ("Pubco").
Key Financial Metrics and Transaction Terms
Valuation and Consideration:
- Base Equity Value: Minovia equity holders (including option and SAFE holders) will receive Pubco ordinary shares valued at $180 million.
- Additional Financing: The base value includes any financing made directly into Minovia prior to closing.
- Earnout Potential: Minovia equity holders are eligible for an additional $57.5 million in Pubco shares contingent on meeting specific share price targets or development milestones.
- Share Pricing: All shares issued to Minovia holders are valued at the "Redemption Price" paid to Launch One public shareholders who redeem their shares.
Financial Statements: This Form 8-K does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for either Launch One or Minovia. It serves as a disclosure of the proposed transaction.
Material Changes and Transaction Structure
Merger Mechanics:
- Company Merger: A newly formed Israeli subsidiary of Pubco will merge with Minovia. Minovia will survive as the surviving company. Existing Minovia shares, in-the-money options, and SAFEs will be cancelled and exchanged for Pubco ordinary shares.
- SPAC Merger: A newly formed Cayman Islands company will merge with Launch One. Launch One will survive. Existing Launch One securities will be cancelled and exchanged for substantially equivalent Pubco securities.
- Result: Pubco will become the publicly traded parent company.
Material Change: The primary change is the shift from a standalone SPAC and a private biotech firm to a combined public entity focused on Minovia's Mitochondrial Augmentation Technology (MAT).
Guidance, Outlook, Risks, and Contingencies
Outlook and Forward-Looking Statements:
- Management anticipates the completion of the business combination subject to shareholder approval and regulatory conditions.
- Future performance depends on the development and therapeutic benefits of Minovia's MAT technology.
- Launch One intends to file a Form F-4 registration statement (including a proxy statement/prospectus) with the SEC.
Risks and Contingencies:
- Transaction Failure: Risks include failure to obtain shareholder approval, inability to secure necessary financing, or failure to obtain regulatory approvals.
- Redemptions: The transaction is subject to adjustments based on shareholder redemption levels.
- Operational Risks: Minovia faces risks related to scaling its business, retaining talent, and the inherent uncertainties of biotechnology development.
- Legal Proceedings: Potential legal challenges following the announcement could disrupt the transaction.
Investor Verification Checklist
- Verify the final Redemption Price per share, as this determines the actual number of shares issued to Minovia stakeholders.
- Review the upcoming Form F-4 Registration Statement and Proxy Statement/Prospectus for definitive terms, risk factors, and financial projections.
- Confirm the status of financing required to complete the transaction and any PIPE (Private Investment in Public Equity) commitments.
- Assess the specific milestones required to trigger the $57.5 million earnout.
- Monitor the shareholder vote outcome and any regulatory approvals required for the cross-border merger.